Tredje AP fonden Has $43.52 Million Stock Position in Stryker Corporation $SYK

Tredje AP fonden grew its stake in shares of Stryker Corporation (NYSE:SYK) by 11.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 110,000 shares of the medical technology company’s stock after buying an additional 11,000 shares during the quarter. Tredje AP fonden’s holdings in Stryker were worth $43,519,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Brighton Jones LLC raised its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Golden State Wealth Management LLC increased its stake in shares of Stryker by 24.1% in the first quarter. Golden State Wealth Management LLC now owns 247 shares of the medical technology company’s stock valued at $92,000 after buying an additional 48 shares during the period. Rossby Financial LCC bought a new position in Stryker in the 1st quarter valued at approximately $80,000. First Horizon Advisors Inc. raised its holdings in Stryker by 14.6% in the 1st quarter. First Horizon Advisors Inc. now owns 2,459 shares of the medical technology company’s stock valued at $916,000 after buying an additional 313 shares during the last quarter. Finally, Mutual Advisors LLC boosted its position in Stryker by 1.7% during the 1st quarter. Mutual Advisors LLC now owns 6,436 shares of the medical technology company’s stock worth $2,349,000 after buying an additional 105 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of several analyst reports. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a report on Saturday, October 18th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Wells Fargo & Company upped their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Finally, Redburn Partners set a $420.00 price objective on Stryker in a research report on Thursday, September 18th. Thirteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $434.16.

Stryker Stock Performance

Shares of SYK opened at $356.15 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm’s fifty day simple moving average is $378.08 and its two-hundred day simple moving average is $380.80. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The stock has a market capitalization of $136.16 billion, a P/E ratio of 47.17, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the previous year, the business earned $2.87 EPS. The firm’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date was Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.